Acquisition strengthens pipeline of companion animal therapeutics for chronic pain, a global market estimated at US$400 million annually1 Purchase price of US$6.72 per share, or...
DUBLIN, Ireland, July 28, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced the following; Recommended Acquisition for Cash by ZOETIS BELGIUM S.A. A WHOLLY-OWNED...
DUBLIN, Ireland, July 10, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced the following; Recommended Acquisition for Cash by ZOETIS BELGIUM S.A. A WHOLLY-OWNED...
DUBLIN, Ireland, July 05, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced the following; In accordance with Rule 2.10 of the Irish Takeover Panel Act 1997, Takeover...
DUBLIN, Ireland, July 03, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced the following: On June 2, 2017, Nexvet Biopharma plc (“Nexvet”) filed a definitive proxy...
WeissLaw LLP Files Class Action Lawsuit Against Nexvet Biopharma PLC PR Newswire NEW YORK, June 19, 2017 NEW YORK, June 19, 2017 /PRNewswire/ -- WeissLaw LLP announced that a class action was...
DUBLIN, Ireland, June 19, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced the following; In accordance with Rule 2.10 of the Irish Takeover Panel Act 1997, Takeover...
DUBLIN, Ireland, June 16, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced the following; Recommended Acquisition for Cash by ZOETIS BELGIUM S.A. A WHOLLY-OWNED...
DUBLIN, Ireland, June 14, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced the following: In accordance with Rule 2.10 of the Irish Takeover Panel Act 1997, Takeover...
DUBLIN, Ireland, June 07, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced the following; Recommended Acquisition for Cash by ZOETIS BELGIUM S.A. A WHOLLY-OWNED...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.